Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859144 · ClinicalTrials.gov registry record · Phase 3
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
A Phase 3 study of HIV Infections and HIV, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 3
- Development phase
- 901
- Enrollment target
- 1
- Study location
NCT00859144 is a Phase 3 study of HIV Infections and HIV that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 901 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00859144, a Phase 3 study of HIV Infections and HIV, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 901 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine methods for involving local community members in programs to teach urban youth about how to prevent transmission of HIV.
Conditions Studied
Interventions
- BEHAVIORAL Reducing the Risk
- BEHAVIORAL Be Proud! Be Responsible!
- BEHAVIORAL Becoming A Responsible Teen (BART)
Study Locations (1)
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859144
The ClinicalTrials.gov registry entry for NCT00859144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 901 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Reducing the Risk is the first listed.
NCT00859144 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00859144 about?
NCT00859144 is a clinical study titled "Training Community Members to Deliver HIV Prevention Programs to Urban Youth". This study will examine methods for involving local community members in programs to teach urban youth about how to prevent transmission of HIV.
What is the current status of trial NCT00859144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2009-03. Estimated completion is 2012-03.
What conditions does trial NCT00859144 study?
This clinical trial studies the following conditions: HIV Infections, HIV.
What interventions are being tested in trial NCT00859144?
The interventions under investigation include: Reducing the Risk (BEHAVIORAL), Be Proud! Be Responsible! (BEHAVIORAL), Becoming A Responsible Teen (BART) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00859144?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859144 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.